Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast
Date:4/27/2010

EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss first quarter 2010 financial results, on Tuesday, May 4, 2010, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).  Financial results for the first quarter ended March 31, 2010 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-619-6547 and using the passcode 26940268.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 26940268 approximately one hour after the teleconference concludes.  The replay will be available through May 18, 2010. 

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.  The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing.  For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report also analyses the market by ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ...
(Date:12/9/2016)... , Dec. 9, 2016  Harmar Mobility, LLC announced today that ... member of the Board of Directors. Photo - ... ... Mr. Dawson,s executive career ... organizations across a variety of industries. He brings to the company ...
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a ... and digital marketing strategies of thousands of pharmacies through ... won Austin Inno,s "50 on Fire" Award ... "We,re pleased to accept the award as one ... , Chief Executive Officer at RxWiki. "Our platform gives ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... the Pennsylvania Cable Network (PCN) during the summer of 2016. The program was ... provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer organizations ... first franchise-wide Quack Gives Back initiative, and we’re very pleased with ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...
Breaking Medicine News(10 mins):